On February 1, 2013 AskAt reported that it began business operations (Press release, AskAt, FEB 1, 2013, View Source [SID1234535067]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AskAt was launched as an independent company from RaQualia Pharma Inc. to focus on developing several strategic programs, including EP4 receptor antagonists, cyclooxygenase (COX-2) inhibitor, and serotonin 5-HT4 partial agonist. AskAt will also work on new projects.

AskAt will seek to implement innovative structures and collaboration-centric platforms to develop these programs, maximize their value, and then license them to pharmaceutical companies worldwide. Part of this process optimization will include partnerships with academia, public funding, as well as private financing on a program-specific basis.